article Open AccessTop 1% cited
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
The American Journal of Gastroenterology · 2016 · Vol. 112(5) · pp. 740–751
Stuart McPherson(Newcastle University)Timothy Hardy(Newcastle University)Jean‐François Dufour(University of Bern)Salvatore Petta(University of Palermo)Manuel Romero‐Gómez(Hospital Universitario Virgen Macarena)Mike Allison(NIHR Cambridge Biomedical Research Centre)Cláudia P. Oliveira(Universidade de São Paulo)Sven Francque(Antwerp University Hospital)Luc Van Gaal(Antwerp University Hospital)Jörn M. SchattenbergDina Tiniakos(Newcastle University)Alastair D. Burt(University of Adelaide)Elisabetta Bugianesi(University of Turin)Vlad Ratziu(Sorbonne Université)Christopher P. Day(Newcastle University)Quentin M. Anstee✉(Newcastle upon Tyne Hospital)
Abstract
The NFS and FIB-4 scores have similar accuracy for advanced fibrosis in patients aged >35 years. However, the specificity for advanced fibrosis is unacceptably low in patients aged ≥65 years, resulting in a high false positive rate. New thresholds for use in patients aged ≥65 years are proposed to address this issue.
Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver Disease and TransplantationMedicineInternal medicineFibrosisGastroenterologyAspartate transaminaseAlanine transaminaseLiver biopsyConfoundingHepatologyReceiver operating characteristic
MeSH terms
AdultAge FactorsAgedAlanine TransaminaseAspartate AminotransferasesBiopsyFalse Positive ReactionsFemaleHumansLiverLiver CirrhosisMaleMiddle AgedPlatelet CountPredictive Value of Tests
Funding
- European Commission
- European Association for the Study of the Liver
Citations
861
FWCI
23.12
field-weighted impact
References
54
Percentile
100%
vs. same field & year
Citations per year
Cited by
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Journal of Hepatology · 2024 · 1,354 citations
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Hepatology · 2023 · 2,046 citations
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Journal of Hepatology · 2021 · 1,641 citations
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Journal of Hepatology · 2018 · 1,972 citations
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Gastroenterology · 2019 · 1,418 citations
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Gastroenterology · 2020 · 3,178 citations
References
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Hepatology · 2012 · 3,804 citations
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Gastroenterology · 2015 · 2,900 citations
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
Hepatology · 2006 · 2,303 citations
Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations
Hepatology · 2009 · 1,143 citations
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Hepatology · 2014 · 2,228 citations
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
Hepatology · 2006 · 4,719 citations
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Hepatology · 2005 · 10,531 citations
FIB-4
Hepatology · 2007 · 2,052 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.